Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 30 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung CancerTerminatedNCT02751385Phase 1Results posted
• An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results posted
• A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET InhibitorCompletedNCT02750215Phase 2Results posted
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02744612Phase 2Results posted
• ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3Results posted
• Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell LymphomaCompletedNCT02736617Phase 2Results posted
• Study of Pexidartinib in Asian Subjects With Advanced Solid TumorsCompletedNCT02734433Phase 1Results posted
• Investigating the Interactions of AZD0530 With Alcohol in Social DrinkersCompletedNCT02732587Phase 1Results posted
• Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid LeukemiaTerminatedNCT02730195Phase 2Results posted
• Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell CarcinomaCompletedNCT02729194Early Phase 1Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
• Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy VolunteersCompletedNCT02723630Phase 1Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDsCompletedNCT02720523Phase 2/3Results posted
• Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFRTerminatedNCT02720185Phase 2Results posted
• Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)CompletedNCT02720068Phase 1Results posted
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedNCT02718300Phase 2Results posted
• A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyActive, not recruitingNCT02717611Phase 2Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerActive, not recruitingNCT02711553Phase 2Results posted
• Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid LeukemiaTerminatedNCT02709083Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)CompletedNCT02708095Phase 2Results posted
• A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)CompletedNCT02706951Phase 3Results posted
• A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateCompletedNCT02706873Phase 3Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDsCompletedNCT02706847Phase 3Results posted
• BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck CancerTerminatedNCT02706691Phase 2Results posted
• Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsTerminatedNCT02706626Phase 2Results posted
• A Study of PRN1008 in Adult Patients With Pemphigus VulgarisCompletedNCT02704429Phase 2Results posted
• A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaTerminatedNCT02703272Phase 3Results posted
• A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileCompletedNCT02702388Phase 2Results posted
• Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT02701634Phase 2Results posted
• Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)TerminatedNCT02695290Phase 4Results posted
• A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic CancerCompletedNCT02694536Phase 3Results posted
• Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCTCompletedNCT02692248Phase 2Results posted
• Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid TumorsCompletedNCT02686164Phase 1Results posted
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)CompletedNCT02684006Phase 3Results posted
• Lenvatinib Efficacy in Metastatic Neuroendocrine TumorsCompletedNCT02678780Phase 2Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs AloneCompletedNCT02675426Phase 3Results posted
• Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast CancerCompletedNCT02673398Phase 2Results posted
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)CompletedNCT02668653Phase 3Results posted
• Nintedanib and Weekly Docetaxel in Lung AdenocarcinomaCompletedNCT02668393Phase 1Results posted
• Influence of Bosentan on the Pharmacokinetics of NintedanibCompletedNCT02667704Phase 1Results posted
• WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02666950Phase 2Results posted
• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast CancerCompletedNCT02659514Phase 2Results posted
• A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid CancerCompletedNCT02657551Phase 2Results posted
• BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the BladderCompletedNCT02657486Not applicableResults posted
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)TerminatedNCT02657369Phase 2Results posted
• Phase II Study of Perindopril and Regorafenib in mCRCCompletedNCT02651415Phase 2Results posted
• Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line TherapyCompletedNCT02649387Phase 2Results posted
• Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa LoaTerminatedNCT02644525Phase 2Results posted
• Ibrutinib as Neoadjuvant Therapy in Localized Prostate CancerCompletedNCT02643667Phase 2Results posted
• Eribulin and Lenvatinib in Advanced Solid TumorsCompletedNCT02640508Phase 2Results posted
• Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue SarcomasCompletedNCT02636725Phase 2Results posted
• Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibCompletedNCT02636322Phase 2Results posted
• Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML TherapiesTerminatedNCT02629692Phase 1/2Results posted
• A Study of LY3337641 in Rheumatoid ArthritisTerminatedNCT02628028Phase 2Results posted
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)CompletedNCT02627963Phase 3Results posted
• A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid LeukemiaTerminatedNCT02627677Phase 3Results posted
• Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)CompletedNCT02626026Phase 1Results posted
• 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast CancerTerminatedNCT02624700Phase 2Results posted
• Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibCompletedNCT02621047Phase 1Results posted
• Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesCompletedNCT02616393Phase 2Results posted
• A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerCompletedNCT02614794Phase 2Results posted
• LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial CancerTerminatedNCT02612194Phase 2Results posted
• A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationCompletedNCT02606877Phase 4Results posted
• Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome SequencingCompletedNCT02604511Phase 2Results posted
• Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and CrizotinibCompletedNCT02604342Phase 3Results posted
• Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic SarcomaTerminatedNCT02601209Phase 1/2Results posted
• Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary TumorsCompletedNCT02599324Phase 1/2Results posted
• Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.TerminatedNCT02598297Phase 3Results posted
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02598193Phase 4Results posted
• Afatinib in NSCLC With HER2 MutationCompletedNCT02597946Phase 2Results posted
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung FibrosisCompletedNCT02597933Phase 3Results posted
• Efficacy Study Of Tofacitinib In Pediatric JIA PopulationCompletedNCT02592434Phase 3Results posted
• A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedNCT02588261Phase 3Results posted
• Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTerminatedNCT02587650Phase 2Results posted
• A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)Active, not recruitingNCT02586857Phase 1/2Results posted
• PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsTerminatedNCT02584647Phase 1/2Results posted
• Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)TerminatedNCT02584634Phase 1/2Results posted
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous MelanomaCompletedNCT02581930Phase 2Results posted
• Axitinib Given on an Individualized Schedule for Metastatic Renal Cell CancerCompletedNCT02579811Phase 2Results posted
• Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination ChemotherapyCompletedNCT02579616Phase 2Results posted
• Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPFCompletedNCT02579603Phase 4Results posted
• A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.CompletedNCT02578316Phase 1Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT02576938Phase 2Results posted
• Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedNCT02575300Phase 2Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• Relative Bioavailability of 2 Oral Formulations of NintedanibCompletedNCT02572752Phase 1Results posted
• BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid MalignanciesCompletedNCT02569476Phase 1Results posted
• Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)TerminatedNCT02568683Phase 1/2Results posted
• Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is RecurrentCompletedNCT02568449Phase 2Results posted
• Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerCompletedNCT02562898Phase 1/2Results posted
• LEO 124249 Ointment in the Treatment of Alopecia AreataCompletedNCT02561585Phase 2Results posted
• Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 TrialCompletedNCT02561455Phase 1/2Results posted
• Trial of TRC105 and Sorafenib in Patients With HCCCompletedNCT02560779Phase 1/2Results posted
• Personalized Targeted Inhibitors Treatment in Renal Cell CancerTerminatedNCT02560012Phase 2Results posted
• A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)TerminatedNCT02553330Phase 2Results posted
• A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02549937Phase 1/2Results posted
• Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple MyelomaTerminatedNCT02548962Phase 1/2Results posted
• Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.CompletedNCT02546674Phase 4Results posted
• Eurosarc Trial of Linsitinib in Advanced Ewing SarcomaCompletedNCT02546544Phase 2Results posted

← Tyrosine Kinase Inhibitors overview